The Founders

Avanish Vellanki and Dr. Robert Doebele founded Rain Therapeutics in April 2017 with the goal of building a cancer-focused biotechnology company aimed at optimal patient selection for improved outcomes.

Targeted Care for Cancer

Rain Therapeutics’ goal is to pursue programs that leverage biomarkers to predict a patient’s potential to respond to therapy, with the hope of supplementing clinical treatment options. The combination of Avanish’s background in the business of biotechnology and Bob’s laboratory and clinical experience across notable precision oncology successes form the basis of a lean development organization offering much needed hope for cancer patients.

Robert Doebele (left) and Avanish Vellanki (right)